Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4064101 | 0.77 | PDE3B (0.48) | ALDH1A1SMN1; SMN2KMT2AKDM4EADORA2B | |
| SCHEMBL29200848 | 0.75 | MAPK14 (0.59) | CFTRALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30783435 | 0.75 | MAPK14 (0.59) | CFTRALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4293106 | 0.75 | PDE3B (0.47) | ALDH1A1KMT2AKDM4EADORA2BADORA1 | |
| SCHEMBL27864221 | 0.73 | ALDH1A1 (0.51) | CFTRALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30783430 | 0.71 | KMT2A (0.70) | ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL29200844 | 0.71 | KMT2A (0.70) | ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL28988615 | 0.68 | CFTR (0.51) | CFTRALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11638904 | 0.68 | LMNA (0.66) | CFTRMEN1KMT2AKDM4EMAPT | |
| SCHEMBL10642119 | 0.67 | KMT2A (0.64) | CFTRALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1596860-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-05-27 | — | — | EP | claimed |
| US-20060211727-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2006-09-21 | — | — | US | claimed |
| EP-1596860-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-23 | — | — | EP | claimed |
| WO-2004073628-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-09-02 | — | — | WO | claimed |
| US-20090239897-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239897-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239897-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550480-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1596860-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20060211727-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2006-09-21 | — | — | US | disclosed |
| EP-1596860-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004073628-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239897-A1 | NOVEL COMPOUNDS | MAPKAPK2, CREBBP, MAPK1 | CFTR 2898/4885ALDH1A1 3499/4885SMN1; SMN2 2180/4885 |
| US-20060211727-A1 | Novel compounds | MAPKAPK2, CREBBP, MAPK1 | CFTR 2898/4885ALDH1A1 3499/4885SMN1; SMN2 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.